GAMBACORTI PASSERINI, CARLO
GAMBACORTI PASSERINI, CARLO
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture
1986 Mussoni, L; Conforti, G; Gambacorti-Passerini, C; Alessio, G; Pepe, S; Vaghi, M; Erba, E; Amato, G; Landoni, F; Mangioni, C; Morasca, L; Semeraro, N; Donati, M
Cancer procoagulant in human tumor cells: evidence from melanoma patients
1986 Donati, M; Gambacorti Passerini, C; Casali, B; Falnga, A; Vannotti, P; Fossati, G; Semeraro, N; Gordon, S
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
1997 Gambacorti-Passerini, C; Le Coutre, P; Mologni, L; Fanelli, M; Bertazzoli, C; Marchesi, E; Di Nicola, M; Biondi, A; Corneo, G; Belotti, D; Pogliani, E; Lydon, N
Anaplastic Lymphoma kinase assay, reagents and composition thereof
2003 Pinna, L; Donella Deana, A; Marin, O; Mologni, L; Gunby, R; GAMBACORTI PASSERINI, C; Scapozza, L
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR)
2003 Piazza, R; Magistroni, V; Tornaghi, L; Andreoni, F; Bungaro, S; Cazzaniga, G; Biondi, A; Pogliani, E; Varella Garcia, M; Corneo, G; GAMBACORTI PASSERINI, C
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels
2003 GAMBACORTI PASSERINI, C; Piazza, R; D'Incalci, M
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
2003 GAMBACORTI PASSERINI, C; Gunby, R; Piazza, R; Galietta, A; Rostagno, R; Scapozza, L
Development of c-Kit-expressing Small-Cell lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment
2004 GAMBACORTI PASSERINI, C; Piazza, R; Tornaghi, L; Pilotti, S; Pogliani, E
SNP MINING BY NANOGEN DEVICE: A SENSITIVE TOOL FOR THE IDENTIFICATION OF BCR/ABL MUTATIONS IN PH+ PATIENTS
2004 Corradi, B; Piazza, R; Monn, K; Masera, G; GAMBACORTI PASSERINI, C; Biondi, A; Cazzaniga, G
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment
2004 Cazzaniga, G; Corradi, B; Piazza, R; Soverini, S; Martinelli, G; GAMBACORTI PASSERINI, C; Biondi, A
Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo
2004 Coluccia, A; Perego, S; Cleris, L; Gunby, R; Passoni, L; Marchesi, E; Formelli, F; GAMBACORTI PASSERINI, C
Oncogenic protein tyrosine kinases
2004 GAMBACORTI PASSERINI, C
ABL INHIBITOR BMS354825 BINDING MODE IN ABELSON KINASE REVEALED BY MOLECULAR DOCKING STUDIES
2005 GAMBACORTI PASSERINI, C; Piazza, R; Gasser, M; Ahmed, S; Scapozza, L
SIGNIFICANT REDUCTION IN FASTING BLOOD GLUCOSE IN NONDIABETIC PH+ CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE
2005 Tornaghi, L; Franceschino, A; Piazza, R; Gnessi, L; Pogliani, E; GAMBACORTI PASSERINI, C
Expression, purification, and inhibition of human RET tyrosine kinase
2005 Mologni, L; Sala, E; Riva, B; Cesaro, L; Cazzaniga, S; Redaelli, S; Marin, O; Pasquato, N; Donella Deana, A; GAMBACORTI PASSERINI, C
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al
2005 Piazza, R; Magistroni, V; Franceschino, A; GAMBACORTI PASSERINI, C
Bim promoter is highly methylated in malignant lymphoid cell lines, leading to downregulation of Bim expression and protection from apoptosis
2005 Piazza, R; Magistroni, V; Andreoni, F; Franceschino, A; GAMBACORTI PASSERINI, C
NPM/ALK co-localizes with, and phosphorylates PSF and other RNA-binding proteins
2005 Galietta, A; Gunby, R; Stano, P; Tucker, P; Carniti, C; Ruchatz, H; Piazza, R; Huang, C; Tartari, C; Puttini, M; Pulford, K; Colombo, E; Bachi, A; GAMBACORTI PASSERINI, C
Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib
2005 GAMBACORTI PASSERINI, C
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate
2005 Perseghin, P; GAMBACORTI PASSERINI, C; Tornaghi, L; Dassi, M; Pioltelli, P; Parma, M; Colnaghi, F; Giudici, G; Elli, E; Fumagalli, M; Ponchio, L; Biondi, A; Pogliani, E